Results 31 to 40 of about 4,527 (165)

“Influence of Clinically Active Graves’ Ophthalmopathy on Spherical Equivalent and Visual Acuity”

Clinical Ophthalmology, 2022
Jasenka Petrovic Jurcevic,1 Marko Jurcevic,2 Mateja Jagic,3 Anamarija Jazbec,4 Kresimir Mandic,5 Jelena Juri Mandic5 1Medical School University of Zagreb, PhD Candidate on the Programme “Biomedicine and Health”, Zagreb, Croatia; 2University of Zagreb ...
Petrovic Jurcevic J, Jurcevic M, Jagic M, Jazbec A, Mandic K, Juri Mandic J   +5 more
doaj  

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source

A Case of Euthyroid Graves’ Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody

Case Reports in Endocrinology, 2018
We report of a case of Graves’ ophthalmopathy presented solely with symptoms of the eyes with normal thyroid function tests and negative immunoreactive TSH receptor autoantibody.
Asami Hotta, Tomohiro Tanaka, Haruka Kato, Shota Kakoi, Yuki Shimizu, Chie Hasegawa, Akiko Hayakawa, Satoshi Yasuda, Kento Ogawa, Shunsuke Ito, Hideomi Ohguchi, Takashi Yagi, Hiroyuki Koyama, Mihoko Kawamura, Kazuhiko Sugitani, Yuichiro Ogura, Takashi Joh, Kenro Imaeda   +17 more
doaj   +1 more source

Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development

Taiwan Journal of Ophthalmology, 2020
Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still
Yazhuo Huang, Sijie Fang, Shuo Zhang, Huifang Zhou   +3 more
doaj   +1 more source

Clinical evaluation of Graves ophthalmopathy [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2012
Introduction. Graves ophthalmopathy is an autoimmune disease, which is the consequence of thyroid dysfunction. Ocular manifestations occur in 50% of patients with Graves disease.
Janićijević-Petrović Mirjana A., Šarenac Tatjana, Srećković Sunčica, Janićijević Katarina, Petrović Marko, Vulović Dejan   +5 more
doaj   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

Advanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves′s ophthalmopathy

Indian Journal of Endocrinology and Metabolism, 2013
Pulse methylprednisolone therapy is the recommended therapy for moderate to severe and active ophthalmopathy, but high dose pulse methylprednisolone therapy is marred by the chances of fulminant hepatic failure and the high cost of therapy. Dexamethasone
Rajeev Philip, Sanjay Saran, Manish Gutch, Pushpaltha Agroyia, Rajiv Tyagi, Keshavkumar Gupta   +5 more
doaj   +1 more source

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang, Ruiyan Liu, Xin Shang, Yu Fu, Ying Wang, Shuxun Yan, Suraiya Saleem   +6 more
wiley   +1 more source

Postural variation of exophthalmometry in Graves′ ophthalmopathy

Indian Journal of Ophthalmology, 1990
30 patients with Graves′ ophthalmopathy were subjected to exophthalmometry in the upright and supine positions to determine if the difference in exophthalmometer readings in these two situations are significantly different and would help in ...
Asad Rajvardhan, Tewari H, Ahuja MMS, Mithal A   +3 more
doaj  

Early Low‐Dose Rituximab for Mild‐to‐Moderate Thyroid Eye Disease: A Preliminary Evaluation of Efficacy and Safety

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Thyroid eye disease (TED) is an autoimmune inflammatory condition linked to thyroid dysfunction, which can result in disfigurement and potential vision loss. Recently, immunomodulatory therapies such as rituximab have demonstrated potential benefit in managing TED.
Ming Lu, Luqiang Wang, Xuelian Zhang, Suraiya Saleem   +3 more
wiley   +1 more source